LDS has developed a wide expertise on Src Family Kinase inhibitors as therapeutic intervention against a number of cancers.
In vitro and in vivo studies have been conducted to advance most promising compounds, including PK, tolerability and efficacy in animal models. Current lead compound shows a clear efficacy in intracranial model of glioblastoma in mice. In vivo PK studies confirmed the ability of the compound to cross the BBB.
More recently, a novel target, the protein DDX3, became part of the oncology arsenal at LDS. In vitro studies are currently on going to profile a library of DDX3 inhibitors.
Moreover, LDS is actively working in the field of Antibody Drug Conjugates (ADC) for tumor targeting and has developed a proprietary ADC technology that comprises some sophisticated linker and conjugation technologies for any kind of highly cytotoxic agent.